|
Metrics and Infographics
In every issue of the Journal we provide unique measurements in the form of charts, tables, diagrams and other infographics. These materials are available here in Microsoft PowerPoint format for your individual use, subject to the Terms & Conditions at the end of this page - any download or other use of these materials implies acceptance of these Terms & Conditions.
Instructions
 This download icon accompanies each figure within the Journal online. Click on the icon to view the slide in a new browser window. Microsoft Windows users may click the icon and choose between the "Open" or Save" commands, or right-click and choose the "Save Target As..." option to download the PowerPoint file.
Available charts are listed below — the linked slides are accessible by all users, and the entire listed content is available exclusively to our authenticated subscribers.
VOLUME 2, NUMBER 1 : JANUARY / FEBRUARY 2004
BioMetrics: Industry projections for the year ahead.
New Year's Executions
Pipeline: More money on clinical trials doesn�t translate into new drugs.
Estimated Drug Development Success Rates
FDA Approval Trends by Type of Application
Number of Published Trial Results
NDA Filing Trends by Year
Current Products in the Research Pipeline
Capital Markets: Big M&A deals are back.
Life Sciences Global M&A Announcements
U.S. Life Sciences Venture Capital Investment
Notable Life Sciences Deals
Biotechnology Valuations for Newly Public Companies
Average Venture Investment for Biotech Companies, by IPO Window
BioIndex: The best- and worst-preforming equities. Plus, investment banks rate life sciences companies.
Investment Bank Ratings of Life Sciences Companies
Top Gainers
Top Decliners
Best- and Worst-Performing Sectors
Life Sciences Market Performance
Industry Sector Breakdown
VOLUME 1, NUMBER 4 : NOVEMBER / DECEMBER 2003
BioMetrics: Life Sciences Lobby
Lobbying Expenditures Among Top Life Science Spenders
Top Health Care Political Campaign Contributors
Political Campaign Donations By Health Care Interests
Percentage of Health Care Campaign Donations Going to Republicans
Top Recipients of Health Political Donations In Congress
Pipeline: Measuring Marketing
Change in Promotion and Research and Development Spending
Marketing and Research and Development in the U.S. Pharmaceutical Industry
Distribution of Promotional Spending Among U.S. Pharmaceutical Companies
Percentage of Average Marketing Spending, by Research Phase
Current Products in the Research Pipeline
Capital Markets: IPO Window Eases Open
Life Sciences Global M&A Announcements
U.S. Life Sciences Venture Capital Investment
Notable Life Sciences Deals
Historical U.S. Life Sciences Venture Capital
U.S. Biotech Industry Fund-Raising
BioIndex: Market Remains Muddled
Analysis of Select Life Sciences IPO Filings
Top Gainers
Top Decliners
Best and Worst Performing Sectors
Life Sciences Market Performance
Industry Sector Breakdown
VOLUME 1, NUMBER 3 : SEPTEMBER / OCTOBER 2003
BioMetrics: Prescription for Generic Drugs
Worldwide Generic-Pharmaceuticals Market
U.S. Generic-Drug Market
Financials of Generic Drug Companies
Revenue of Drugs with Pending U.S. Patent Expiry
Pipeline: Send Out for R&D
Global Spending for Outsourced R&D
U.S. Outsourced Clinical Trial Research
Worldwide Outsourced Drug Discovery Market
Book-to-Bill Ratios for Contract Research Organizations
Current Products in the Research Pipeline
Capital Markets: Financing Finds Its Footing
U.S. Life Sciences Venture Capital Investment
Life Sciences Global M&A Announcements
VC Funding to Life Sciences Sectors
VC Funds Raised and Commitments Waived
Early Stage as a Percentage of Venture Capital
Notable Life Sciences Deals
BioIndex: Market Keeps Its Nerve
Institutional Holdings
Top Gainers
Top Decliners
Best and Worst Performing Sectors
Life Sciences Market Performance
VOLUME 1, NUMBER 2 : JULY / AUGUST 2003
BioMetrics: Figuring Out Pharmacogenomics
Orphan Drug Approvals
Market Size of Pharmacogenomics Tools
Market Share of Pharmacogenomics Tools, by Company
Pharmaceutical Licensing Agreements, by Technology Type
Pipeline: R&D Growth Stalls
U.S. R&D Investment and New Drug Approvals
R&D Spending, by Type of Company
R&D Spending, by Research Phase
Selected Companies with Increasing and Decreasing Research and Development Spending
Current Products in the Research Pipeline
Capital Markets: Investors Hesitate
U.S. Life Sciences Venture Capital Investment
Life Sciences Global M&A Announcements
Public and Private Financing by Type in the U.S. Biotech Industry
Notable Second Quarter Life Sciences Deals
Strategic Partnering for Top 20 Pharmaceutical Companies by Sales
Debt for Public Life Sciences Companies
BioIndex: Springing in Like a Lion
Top Gainers and Top Decliners
Top Companies in the Best-Performing Sectors
Best and Worst Performing Sectors
Industry Sector Breakdown
Life Sciences Market Performance
Terms & Conditions
Annotations and Attribution - Each image and PowerPoint® file may include notes, source attribution, and copyright information; all of that information must be included with the image and or file whenever it is used. Image size and color may be altered, or the image may be reproduced in its entirety, but no legend, notes, source attribution or copyright information may be deleted for any reason.
Copyright - These images and files are copyrighted, and all rights are reserved; they may be used in presentations and individual documents, but cannot be re-published online or in printed form without the express written consent of the Acumen Journal of Life Sciences.
Editorial Policy - The Acumen Journal of Life Sciences reserves the right to alter or delete material from this site at any time.
Indemnification - You agree to indemnify, defend and hold harmless the Acumen Journal of Life Sciences, its officers, directors, employees, agents, suppliers and third party partners from and against all losses, expenses, damages and costs, including reasonable legal fees, resulting from any violation by you of these Terms & Conditions, or any activity related to these materials.
Timeliness of Information - The Acumen Journal of Life Sciences uses reasonable efforts to include accurate and up to date information in the site. However, since information changes so quickly, the Acumen Journal of Life Sciences is unable to make any warranties or representations as to its accuracy. The Acumen Journal of Life Sciences FURTHER ASSUMES NO LIABILITY OR RESPONSIBILITY AS TO THE RELIABILITY, ACCURACY, VALIDITY, TIMELINESS, USEFULNESS OR COMPLETENESS OF ANY INFORMATION ON THE SITE.
Microsoft PowerPoint® and Microsoft Windows® are registered trademarks of Microsoft® Corporation
 |
